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A B S T R A C T
Thrombocytopenia in patients with solid malignancy can be caused by bone marrow involvement or toxicity from anticancer therapy;
however, it could rarely be the first presentation of a tumor such as breast cancer or lymphoma. Hematological paraneoplastic syndromes
such as paraneoplastic thrombocytopenia and/or immune thrombocytopenic purpura (ITP) are well described as secondary findings
simultaneously with malignancies such as breast cancer and lymphoma. Other hematological conditions such as severe amegakaryocytic
thrombocytopenia, thrombotic thrombocytopenic purpura (TTP), and myelodysplastic syndromes (MDS) have also rarely been described as
a possible paraneoplastic process complicating solid tumors. On the one hand, occult disseminated malignancy may mimic ITP and TTP,
leading to diagnostic and therapeutic problems. On the other hand, thrombocytopenia could be the first manifestation of cancer.
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INTRODUCTION
Thrombocytopenia is a common problem in oncology. It is
often related to a treatment effect from cytotoxic agents or is
the result of bone marrow involvement. Thrombocytopenia
could rarely be the first presentation of a solid tumor such as
breast cancer or lymphoma. It is debatable whether these
represent incidental findings of two existing common
pathologies or a paraneoplastic ‘‘distant’’ manifestation of
cancer. This is a review of thrombocytopenia in solid tumors
not caused by bone marrow involvement or by toxicity from
anticancer therapy.
Paraneoplastic syndromes are systemic manifestations of
cancer that cannot readily be explained by the local or
metastatic effects of a tumor or of hormones indigenous to
the tissue in which the tumor arises. The syndromes fall into
four broad groups in which the patient has endocrine,
neurological, hematological/vascular, or dermatological dis-
ease [1]. Paraneoplastic syndromes can also be defined as
‘‘disorders caused by cancer, but not a direct result of cancer
invasion of the affected tissue or organ’’.
The first unequivocal paraneoplastic syndrome was prob-
ably described in 1865 by Armand Trousseau [1–3] who
described migratory thrombophlebitis which affected some
patients not known to be otherwise ill. The venous occlusions
were often migratory, affecting one site, clearing sponta-
neously and then affecting another site. Trousseau indicated
that the disorder can complicate visceral cancer, including
gastric cancer [2]. He recognized that the disorder which now
carries his name [4] occurred because ‘‘the blood of cachectic
persons has a strong tendency to coagulate’’ [3]. This was
proven later to be correct [5]. Trousseau died in 1867 of the
disease he had described i.e., migratory thrombophlebitis and
predicted that he had an occult gastric cancer, which he did
on autopsy [1, 6].
There is a plethora of publications in the field of
neurological paraneoplastic disorders (more than 8000 in
PubMed) but not in hematological paraneoplastic syndromes
such as paraneoplastic thrombocytopenia and immune
thrombocytopenic purpura (ITP).
Although paraneoplastic syndromes are rare, their recogni-
tion by the physician is important for several reasons. In some
patients, symptoms precede the diagnosis of cancer, and this
can lead to the detection of an otherwise occult cancer that
could potentially be curable.
In patients known to have cancer, paraneoplastic syndromes
may be confused with metastatic or non-metastatic complica-
tions of cancer. Obviously, other potentially reversible causes
must be carefully excluded before a diagnosis of a
paraneoplastic syndrome is made. A number of paraneoplas-
tic antigens are frequently expressed in the general population
of cancer patients, and these may elicit tumor immune
responses in the absence of autoimmune disease.
THROMBOCYTOPENIA AND MALIGNANCY
The primary regulator of the platelet count in humans is
thrombopoietin, a glycoprotein that is produced primarily in
the liver and cleared primarily by platelets and their
precursors [7, 8]. Thrombopoietin induces the growth and
development of megakaryocytes [9]; levels fluctuate with
changes in platelet count due to variations in clearance.
Interleukin-11 induces a modest increase in platelet counts,
but is not required for thrombopoiesis [10–12].
Thrombocytopenia that is encountered in an oncology
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practice may be caused by the effects of both cytotoxic
chemotherapy and novel agents such as bortezomib or after
multiple cycles of treatment with thrombocytopenic medica-
tion. Other causes include liver disease with decreased
thrombopoietin levels, immune destruction, particularly in
patients with lymphoid malignancies or infection with the
human immunodeficiency virus, and sequestration.
IMMUNE THROMBOCYTOPENIC PURPURA
AND MALIGNANCY
ITP is the one of the most common autoimmune disorders.
It results from accelerated platelet destruction after the
binding of autoreactive antibodies to platelets [13]. It is
estimated that this entity affects approximately 1 in 10000
people among the general population. Most patients with ITP
have detectable immunoglobulin (Ig)G and IgM antibodies
against platelet glycoprotein complexes on their platelets or
in their plasma [14].
ITP AND BREAST CANCER
In the published oncology literature, most patients with ITP
concurrently with breast cancer had a prolonged interval
between the two diseases, suggesting that ITP and breast
cancer were completely coincidental [15–21]. Unless splenic
metastasis or bone marrow infiltration by tumor cells is
shown by radiological, scintigraphic, or histopathologic
examinations, the association between ITP and breast cancer
could probably be considered unrelated, i.e., not paraneo-
plastic. ITP may respond to steroid therapy before the
diagnosis of breast cancer and during the follow-up period.
In the small number of reported cases of ITP and breast
cancer, curative surgery followed by adjuvant chemotherapy in
early breast cancer did not prevent the relapse of ITP in the
postoperative period. Stable platelet counts have been
maintained in patients who had chemotherapy, although the
reported follow-up has been relatively short.
Of the 21 reported cases, only two patients had splenic
metastasis from breast cancer [22], and bone marrow
metastasis was present in seven of the 21 cases (30%) [16–
21]. Immune-mediated platelet destruction and the presence
of serum platelet agglutinins in solid tumors associated with
ITP are possible reasons in the patient without any evidence
of metastases [17].
Often in patients with ITP and a new presentation of breast
cancer, there is a concern about the safety of adjuvant
chemotherapy in the face of thrombocytopenia.
Immunosuppression from corticosteroids and/or chemotherapy
often increases the platelet count, albeit temporarily. Therefore,
the presence of a diagnosis of ITP should not prohibit breast
cancer patients from receiving adjuvant chemotherapy. With the
advent of therapies involving novel non-cytotoxic mechanisms
of action, new challenges will be encountered. For instance,
there are no reports on the effect of antiangiogenic agents such
as bevacizumab on ITP. With the introduction of these agents
into clinical practice, this question will need to be addressed in
future clinical trials.
ITP AND HODGKIN LYMPHOMA (HL)
The simultaneous occurrence of autoimmune disorders such
as ITP and Hodgkin lymphoma (HL) is not very uncommon
[23–25]. A review of the British National Lymphoma
Investigation (BNLI) registry reported eight patients with ITP
in association with HL. The patients were heterogeneous for
initial stage of HL, histology, and treatment received. The
median time from diagnosis of HL to diagnosis of ITP was
23 months (range 3–57 months). Six of eight patients were in
complete remission at diagnosis of ITP, one was in relapse,
and one was undergoing first-line chemotherapy. Of those
patients developing ITP in remission, only one subsequently
relapsed. The ITP responded to a single course of oral
prednisolone in six of the eight patients. Thus, the occurrence
of ITP in patients with HL was interpreted to be independent of
the activity of the lymphoma, responding to therapy as for
primary ITP without a prognostic significance [26].
ITP AND NON-HODGKIN LYMPHOMAS (NHL)
ITP is a relatively common immuno-hematologic complication
in non-Hodgkin lymphomas (NHLs) and may complicate the
treatment. A retrospective analysis from a single Austrian center
combined with previously published cases of NHLs (excluding
chronic lymphocytic leukemia) associated with ITP was
published [27]. The prevalence of ITP in NHL (without chronic
lymphocytic leukemia) in four large studies (1850 patients) was
0.76% (range 0–1.8%). The highest prevalence of ITP was in the
following lymphoma subtypes: follicular lymphomas 1.2%,
marginal zone lymphoma 4%, mantle cell lymphoma 9%, and T-
cell lymphomas 11.1% [27]. Similar to the reported cases with
simultaneous breast cancer and ITP, about half the patients had
ITP prior to the diagnosis of lymphoma. No sustained
remissions were documented in patients treated with steroids
alone. On the other hand, sustained complete remissions were
observed after specific antilymphoma therapy. Chemotherapy
was the best treatment in many NHL patients with ITP compared
with standard treatment for ITP. However, ITP in patients with
NHL was a complicating factor adding new challenges to the
treatment of these patients [27].
ITP AND OTHER SOLID TUMORS
There are two individual reports of patients with lung cancer
presenting with ITP. Both cases were from Japan, and the ITP
is reported to have stabilized after treatment of the lung
cancer in both cases. In one patient, treatment was surgical,
and the other patient received chemotherapy containing
cisplatin and etoposide [28, 29].
Individual case reports with ovarian, esophageal, gastric,
and pancreatic adenocarcinoma presenting as ITP have also
been reported [30–33].
SOLID TUMORS AND THROMBOCYTOPENIA
FROM MYELODYSPLASTIC SYNDROME (MDS)
Severe amegakaryocytic thrombocytopenia and MDS have
rarely been described as a possible paraneoplastic process
complicating solid tumors, including lung cancer [34].
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Although varying degrees of thrombocytopenia are seen in
approximately 25% of patients with MDS, it is unusual for the
disease to present with isolated, severe thrombocytopenia [35].
In addition, amegakaryocytic thrombocytopenia has been
described as a paraneoplastic syndrome complicating thy-
moma and NHL [36, 37]. In a cohort of 155 patients with
MDS, 21 presented with malignant solid tumors.
Myelodysplasia was present after the diagnosis of cancer in
eight patients (interval between the diagnosis of both
conditions, 18 months; median survival, 49.5 months),
simultaneously with diagnosis in 11 (median survival,
8 months), and before malignancy in two patients (interval
between the diagnosis of both conditions, 47 and 7 months).
In this cohort, one patient was given chemotherapy for lung
cancer, and three patients received radiotherapy for adeno-
carcinoma of the kidney and cancer of the prostate. At the
time of diagnosis of MDS, nine patients already presented
metastatic spread. Fourteen patients died, 10 as a result of
tumor-related complications, and four because of transfor-
mation to acute leukemia [34].
MDS patients present a higher incidence of malignant
tumors than the general population [35]. The occurrence of
MDS in cancer patients may be considered to be related to the
malignancy rather than an independent phenomenon [35].
THROMBOTIC THROMBOCYTOPENIC
PURPURA (TTP) AND MALIGNANCY
Thrombotic thrombocytopenic purpura and the hemolytic
uremic syndrome (TTP-HUS) are related and uncommon
disorders with a high fatality and complication rate if untreated.
Plasma exchange therapy has been shown to produce high
response rates and improve survival in patients with many forms
of TTP-HUS. Patients with disseminated malignancy who
present with microangiopathic hemolytic anemia and thrombo-
cytopenia may be misdiagnosed as TTP, resulting in inappropri-
ate plasma exchange treatment, a procedure with major risks,
and delay of appropriate chemotherapy.
A retrospective cohort study of 178 consecutively treated
patients with TTP-HUS analyzed whether clinical or labora-
tory characteristics could predict for important short- and
long-term outcome measures. One hundred and seventy-one
patients (96%) received plasma exchange as the principal
treatment. The rate of complete response was 65% or 55%;
the rate of relapse was 18%. Seventy-two percent of the cohort
had an idiopathic TTP-sporadic HUS, whereas 17% had an
underlying cancer. The estimated overall 5-year survival was
significantly worse in those with an underlying cancer [38].
A registry review of TTP-HUS has reported that 10 of 351
patients who were initially diagnosed with TTP and treated with
plasma exchange were subsequently discovered to have
disseminated malignancy [39]. Only one patient had a history
of cancer. In these 10 patients, neurologic abnormalities,
hematocrit, platelet count, and serum creatinine were not
different from the 133 concurrent patients with idiopathic TTP.
The final diagnoses included eight different malignancies:
breast carcinoma (two patients), non-small cell lung cancer
(two patients), pancreatic carcinoma, renal carcinoma,
myelodysplasia (refractory anemia with excess blasts), acute
lymphoblastic leukemia, diffuse large B-cell lymphoma, and
Kaposi’s sarcoma (one patient each).
Patients with disseminated malignancy had a longer
duration of symptoms, more frequent presence of respiratory
symptoms, higher lactate dehydrogenase levels, and more
often failed to respond to plasma exchange treatment.
Diagnosis of malignancy was made by bone marrow biopsy
in six patients but not until autopsy in two patients [39].
A systematic literature review identified 19 additional
patients, reported from 1965 to 2005, in whom TTP or HUS
was initially suspected and systemic malignancy was subse-
quently discovered. Fourteen different malignant disorders
were diagnosed in these 29 patients [39].
In another retrospective series, out of 77 patients with the
primary diagnosis of TTP, nine had active cancer. Six patients
had the classical triad of TTP, but three patients had
thrombocytopenia and microangiopathic hemolytic anemia.
Among the seven patients who had TTP in the absence of
chemotherapy during the three preceding months, six had bone
marrow metastasis with secondary myelofibrosis. None of those
patients was known to have idiopathic myelofibrosis prior to the
diagnosis of TTP, and splenomegaly was not present [40].
Occult disseminated malignancy may mimic TTP. A search
for systemic malignancy, including a bone marrow biopsy, is
appropriate when patients with TTP have atypical clinical
features or fail to respond to plasma exchange.
CONCLUSIONS
Thrombocytopenia could rarely be the first presentation of a
solid tumor such as breast cancer or lymphoma.
Hematological paraneoplastic syndromes, such as paraneo-
plastic thrombocytopenia and ITP, are rare but well described
in several malignancies including breast cancer and lym-
phoma. Other hematological conditions such TTP and MDS
have also rarely been described as possible paraneoplastic
processes complicating solid tumors. Furthermore, occult
disseminated malignancy may mimic TTP. When thrombo-
cytopenia occurs during the course of a solid tumor, with no
obvious clinical and laboratory relationship, it can be
speculated that this could be an immunologic mechanism
and is rarely the first manifestation of the neoplasm. A search
for systemic malignancy in these circumstances is warranted.
Disclosure: The authors declare no conflict of interest.
Acknowledgments: The authors are grateful to Professor Jerome
Posner (MSKCC) for sharing information and references from his
unpublished book on paraneoplastic neurologic disorders, and to Ms
Judith Lampron for her valuable editorial assistance.
REFERENCES
1. Posner J. Paraneoplastic Sydnromes. New York; 2009 (unpublished; in
preparation).
2. Trousseau A. Phlegmasia alba dolens. Clin Med Hotel Dieu de Paris. 1865(3):94.
3. Trousseau A. Phlegmasia alba dolens. In: Cormak JRT, ed. Lectures on Clinical
Medicine. Philadelphia: Lindsay & Blakiston; 1873:859–890.
Thrombocytopenia in solid tumors
www.slm-oncology.com 91 EJCMO 2010; 2:(2). June 2010
4. Sack GH, Jr., Levin J, Bell WR. Trousseau’s syndrome and other
manifestations of chronic disseminated coagulopathy in patients with
neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine
(Baltimore). 1977;56(1):1–37.
5. Varki A. Trousseau’s syndrome: multiple definitions and multiple
mechanisms. Blood. 2007;110(6):1723–1729.
6. Soubiran A. [‘‘Is he king of some island?’’ or the last Christman of
Trousseau]. Presse Med. 1967;75(54):2807–2810.
7. Kaushansky K. Thrombopoietin: the primary regulator of platelet
production. Blood. 1995;86(2):419–431.
8. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology
and evaluation of clinical studies. Blood. 2002;100(10):3457–3469.
9. Sitnicka E, Lin N, Priestley GV, et al. The effect of thrombopoietin on the
proliferation and differentiation of murine hematopoietic stem cells.
Blood. 1996;87(12):4998–5005.
10. Nandurkar HH, et al. Adult mice with targeted mutation of the
interleukin-11 receptor (IL11Ra) display normal hematopoiesis. Blood.
1997;90(6):2148–2159.
11. Nandurkar HH, Robb L, Begley CG. The role of IL-II in hematopoiesis as
revealed by a targeted mutation of its receptor. Stem Cells. 1998;16(Suppl
2):53–65.
12. Begley CG, Basser RL. Biologic and structural differences of thrombo-
poietic growth factors. Semin Hematol. 2000;37(2 Suppl 4):19–27.
13. Berchtold P, McMillan R. Therapy of chronic idiopathic thrombocyto-
penic purpura in adults. Blood. 1989;74(7):2309–2317.
14. Berchtold P, Wenger M. Autoantibodies against platelet glycoproteins in
autoimmune thrombocytopenic purpura: their clinical significance and
response to treatment. Blood. 1993;81(5):1246–1250.
15. Khasraw M, Baron-Hay S. Immune thrombocytopenic purpura (ITP) and
breast cancer. Does adjuvant therapy for breast cancer improve platelet
counts in ITP? Ann Oncol. 2009;20(7):1282–1283.
16. Peffault de Latour R, et al. Breast cancer associated with idiopathic
thrombocytopenic purpura: a single center series of 10 cases. Am J Clin
Oncol. 2004;27(4):333–336.
17. Gencosmanoglu R, Unalan P, Kir G, et al. Cancer and Immune
Thrombocytopenic Purpura: Is there any Association between these 2
Distinct Diseases? Breast Care. 2007;2:317–320.
18. Wahid FS, et al. Breast carcinoma presenting as immune thrombocyto-
penic purpura. Int J Hematol. 2001;73(3):399–400.
19. Porrata LF, et al. Idiopathic thrombocytopenic purpura associated with
breast cancer: a case report and review of the current literature. Am J Clin
Oncol. 1999;22(4):411–413.
20. Igarashi T, et al. Successful treatment by radiation and hormone therapy
of isolated local recurrence of breast cancer 24 years after mastectomy
accompanied by immune thrombocytopenia: a case report. Jpn J Clin
Oncol. 1998;28(4):270–275.
21. Ustun C, et al. Association of breast cancer and immune thrombocyto-
penic purpura. South Med J. 2002;95(11):1335–1337.
22. Cummings OW, Mazur MT. Breast carcinoma diffusely metastatic to the
spleen. A report of two cases presenting as idiopathic thrombocytopenic
purpura. Am J Clin Pathol. 1992;97(4):484–489.
23. Kirshner JJ, Zamkoff KW, Gottlieb AJ. Idiopathic thrombocytopenic
purpura and Hodgkin’s disease: report of two cases and a review of the
literature. Am J Med Sci. 1980;280(1):21–28.
24. Murphy WG, et al. Hodgkin’s disease presenting as idiopathic
thrombocytopenic purpura. Postgrad Med J. 1984;60(707):614–615.
25. Saitoh T, et al. Hodgkin lymphoma presenting with various immunologic
abnormalities, including autoimmune hepatitis, Hashimoto’s thyroiditis,
autoimmune hemolytic anemia, and immune thrombocytopenia. Clin
Lymphoma Myeloma. 2008;8(1):62–64.
26. Bradley SJ, Hudson GV, Linch DC. Idiopathic thrombocytopenic purpura
in Hodgkin’s disease: a report of eight cases. Clin Oncol (R Coll Radiol).
1993;5(6):355–357.
27. Hauswirth AW, et al. Autoimmune thrombocytopenia in non-Hodgkin’s
lymphomas. Haematologica. 2008;93(3):447–450.
28. Nonami Y, et al. Double lung cancer combined with idiopathic
thrombocytopenic purpura—a case report. J Cardiovasc Surg. 1999;40(6):
889–892.
29. Ogawa R, et al. Chemotherapy for small cell lung cancer in a patient with
idiopathic thrombocytopenic purpura. Respir Med Extra. 2007;3(3):117–119.
30. Chehal A, et al. Idiopathic thrombocytopenic purpura and ovarian cancer.
Eur J Gynaecol Oncol. 2003;24(6):539–540.
31. Shutt JD, et al. Oesophageal carcinoma and refractory idiopathic
thrombocytopenic purpura: a challenging combination. Eur J
Gastroenterol Hepatol. 2004;16(8):791–793.
32. Wakata N, et al. Autoimmune thrombocytopenic purpura, autoimmune
hemolytic anemia and gastric cancer appeared in a patient with
myasthenia gravis. Intern Med. 2006;45(7):479–481.
33. Bir WB, Fakih MG. Idiopathic thrombocytopenic purpura in a newly
diagnosed pancreatic adenocarcinoma. J Pancreas. 2006;7(6):647–650.
34. Sans-Sabrafen J, et al. Myelodysplastic syndromes and malignant solid
tumors: analysis of 21 cases. Am J Hematol. 1992;41(1):1–4.
35. Hematologique GFdM. French registry of acute leukemia and myelodys-
plastic syndromes. Age distribution and hemogram analysis of the 4496
cases recorded during 1982–1983 and classified according to FAB criteria.
Cancer. 1987;60(6):1385–1394.
36. Lugassy G. Non-Hodgkin’s lymphoma presenting with amegakaryocytic
thrombocytopenic purpura. Ann Hematol. 1996;73(1):41–42.
37. Maslovsky I, et al. Malignant thymoma complicated by amegakaryocytic
thrombocytopenic purpura. Eur J Intern Med. 2005;16(7):523–524.
38. Levandovsky M, et al. Thrombotic thrombocytopenic purpura-hemolytic
uremic syndrome (TTP-HUS): a 24-year clinical experience with 178
patients. J Hematol Oncol. 2008;1:23.
39. Francis KK, et al. Disseminated malignancy misdiagnosed as thrombotic
thrombocytopenic purpura: q report of 10 patients and a systematic
review of published cases. Oncologist. 2007;12(1):11–19.
40. Chang JC, Naqvi T. Thrombotic thrombocytopenic purpura associated
with bone marrow metastasis and secondary myelofibrosis in cancer.
Oncologist. 2003;8(4):375–380.
European Journal of Clinical & Medical Oncology
EJCMO 2010; 2:(2). June 2010 92 www.slm-oncology.com
Copyright of European Journal of Clinical & Medical Oncology is the property of San Lucas Medical and its
content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's
express written permission. However, users may print, download, or email articles for individual use.
